Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference)

Area of Science:

• Cardiology
• Urology
• Pharmacology

Background:

• Erectile dysfunction (ED) is increasingly recognized as a potential indicator of underlying cardiovascular disease (CVD).
• Endothelial dysfunction and nitric oxide pathways are implicated in both ED and atherosclerosis.
• Managing ED requires careful consideration of cardiovascular risks associated with sexual activity and potential drug interactions.

Framework:

• The Second Princeton Consensus Conference refined a risk stratification algorithm for evaluating cardiovascular risk during sexual activity in men with ED.
• Patients are categorized into low, intermediate, and high-risk groups based on their cardiovascular status.
• Emphasis is placed on comprehensive risk factor evaluation and management for all men with ED.

Implementation:

• The consensus reviewed safety and drug interaction data for phosphodiesterase (PDE)-5 inhibitors (sildenafil, tadalafil, vardenafil) in men with ED and CVD.
• Lifestyle interventions, including weight loss and physical activity, are increasingly supported for ED management, especially in patients with comorbid CVD.
• Guidelines are provided for managing patients on PDE-5 inhibitors in emergency settings.

Implications:

• This consensus clarifies the cardiovascular risk assessment and management for men with ED.
• It highlights the importance of a multidisciplinary approach involving cardiologists and urologists.
• Further research is recommended on the broader therapeutic applications of PDE-5 inhibitors in cardiovascular and other medical conditions.